Critical Review: Jin Medical International (NASDAQ:ZJYL) versus Haemonetics (NYSE:HAE)

Jin Medical International (NASDAQ:ZJYL) and Haemonetics (NYSE:HAE) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.

Risk and Volatility

Jin Medical International has a beta of 7.24, meaning that its share price is 624% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.

Profitability

This table compares Jin Medical International and Haemonetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jin Medical International	N/A	N/A	N/A
Haemonetics	7.29%	27.30%	9.59%

Valuation & Earnings

This table compares Jin Medical International and Haemonetics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jin Medical International	$20.69 million	0.92	$1.19 million	N/A	N/A
Haemonetics	$1.33 billion	2.47	$97.31 million	$2.02	35.92

Haemonetics has higher revenue and earnings than Jin Medical International.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Jin Medical International and Haemonetics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jin Medical International	1	0	0	0	1.00
Haemonetics	1	3	6	1	2.64

Haemonetics has a consensus price target of $78.33, suggesting a potential upside of 7.96%. Given Haemonetics’ stronger consensus rating and higher probable upside, analysts clearly believe Haemonetics is more favorable than Jin Medical International.

Institutional & Insider Ownership

99.7% of Haemonetics shares are held by institutional investors. 2.1% of Haemonetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Haemonetics beats Jin Medical International on 12 of the 13 factors compared between the two stocks.

About Jin Medical International

Jin Medical International Ltd. engages in the design, development, manufacturing, and sale of wheelchair and other living aids products for people with disabilities or impaired mobility in China and internationally. It also offers oxygen concentrators and bathing machines. The company was founded in 2006 and is based in Changzhou, China. Jin Medical International Ltd. is a subsidiary of Jolly Harmony Enterprises Limited.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.